Clinical data | |
---|---|
Other names | VERU-111[1][2][3] |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C21H19N3O4 |
Molar mass | 377.400 g·mol−1 |
3D model (JSmol) | |
| |
|
Sabizabulin is an investigational new drug that is being evaluated for the treatment of castration-resistant prostate cancer[4] and in SARS-CoV-2 (COVID-19) infections.[5] It is a tubulin polymerization inhibitor.[6][7]
Sabizabulin is chemical compound from the group of indole and imidazole derivatives that was first reported in 2012 by Dalton, Li, and Miller.[8]
NCT04842747
was invoked but never defined (see the help page).